Pealkiri: 

CCL3L1 copy number is a strong genetic determinant of HIV seropositivity in Caucasian intravenous drug users

Autorid: Huik K , Sadam M , Karki T , Avi R , Krispin T , Paap P , Rüütel K , Uusküla A , Talu A , Abel-Ollo K , Lutsar I
Väljaandja/tellija: The Journal of Infectious Diseases
Märksõnad: HIV, AIDS, hepatiit, C-hepatiit, B-hepatiit, narkomaania
Välja antud: 2010
Tüüp: Teaduslik artikkel/kogumik
Viide: Huik, K.; Sadam, M.; Karki, T.; Avi, R.; Krispin, T.; Paap, P.; Rüütel, K.; Uusküla, A.; Talu, A.; Abel-Ollo, K.; Lutsar, I. (2010). CCL3L1 copy number is a strong genetic determinant of HIV seropositivity in Caucasian intravenous drug users. The Journal of Infectious Diseases, 730 - 739.
Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2836481/
Alamvaldkonnad:Sõltuvusainete tarvitamine
Nakkushaigused
Kirjeldus: Abstract

BACKGROUND: A high copy number of CCL3L1, the most potent human immunodeficiency virus (HIV)-suppressive chemokine, associates with reduced HIV susceptibility. Whether CCL3L1 influences acquisition of multiple blood-borne infections (eg, hepatitis C virus [HCV], HIV, and hepatitis B virus [HBV] infections), which occur commonly among injection drug users (IDUs), is unknown.

METHODS: We determined CCL3L1 copy number by real-time polymerase chain reaction among 374 Caucasian IDUs from Estonia; 285 were HCV positive, 208 were HIV positive, 177 were HCV and HIV positive, and 57 were HCV and HIV negative.

RESULTS: In univariate and multivariate analyses, HCV and HBV seropositivity and duration of IDU each strongly predicted HIV seropositivity. A high CCL3L1 copy number (>2) was associated with an 80% reduced risk of acquiring HIV infection after adjusting for age, sex, HCV and HBV status, CCR5-Delta32 polymorphism, and IDU duration (odds ratio, 0.20; 95% confidence interval, 0.09-0.45). By contrast, CCL3L1 gene dose did not influence HCV seropositivity. Among HCV-positive IDUs, there was a 3.5-fold overrepresentation and 65% underrepresentation of a high CCL3L1 copy number among HCV-positive, HIV-negative subjects and HCV-positive, HIV-positive subjects, respectively.

CONCLUSION: Among IDUs with extensive exposure to HCV and HIV, CCL3L1 copy number is a major determinant of HIV seropositivity but not of HCV seropositivity. The contrasting distribution of a protective high CCL3L1 copy number among HCV-positive, HIV-negative IDUs versus HCV-positive, HIV-positive IDUs may reflect that HIV preferentially selects for subjects with a low CCL3L1 gene dose.